34803-66-2

Basic information

• Product Name: 1-(2-Pyridyl)piperazine
• Synonyms: 2-pyridyl piperazine;1-(2-PYRIDYL)PIPERAZINE, 99.5+%;2-(1-piperazino)pyridine;2-piperazinopyridine;1-(Pyridin-2-yl)piperazine 98%;N-(4-PYRIDYL) PIPERAZINE;1-PYRIDIN-2-YL-PIPERAZINE >98%;1-(2-Pyridyl)piperazine ,98%
• CAS NO: 34803-66-2
• Molecular Formula: C₉H₁₃N₃
• Molecular Weight: 163.22
• EINECS: 252-220-3
• Product Categories: Piperidines, Piperidones, Piperazines;pharmacetical;API intermediates;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 34803-66-2.mol
• Article Data: 20

Chemical Properties

• Melting Point: 92-94
• Boiling Point: 120-122 °C2 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: Clear colorless to yellow/Liquid
• Density: 1.072 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000467mmHg at 25°C
• Refractive Index: n20/D 1.595(lit.)
• Storage Temp.: Flammables area
• Solubility: Soluble in Chloroform, Methanol.
• PKA: 8.63±0.10(Predicted)
• Water Solubility: >500 g/L (20 ºC)
• Sensitive: Air Sensitive
• BRN: 140423
• CAS DataBase Reference: 1-(2-Pyridyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Pyridyl)piperazine(34803-66-2)
• EPA Substance Registry System: 1-(2-Pyridyl)piperazine(34803-66-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 2735
• WGK Germany: 3
• F: 10-34
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 34803-66-2(Hazardous Substances Data)

Usage

Chemical Properties

clear colourless to yellow liquid

Uses

Different sources of media describe the Uses of 34803-66-2 differently. You can refer to the following data:
1. 1-(2-Pyridyl)piperazine is a compound that belongs to a class of selective α2-adrenoceptor antagonists. 1-(2-Pyridyl)piperazine shows sympatholytic activity. 1-(2-Pyridyl)piperazine is also a metaboli te of Azaperone (A802200).
2. 1-(2-Pyridyl)piperazine was used to determine the aliphatic and aromatic isocyanates in air.

General Description

1-(2-Pyridyl)piperazine is a piperazine derivative.

InChI:InChI=1/C9H13N3/c1-2-4-11-9(3-1)12-7-5-10-6-8-12/h1-4,10H,5-8H2/p+2

Upstream product

• 110-85-0 piperazine 
• 109-09-1 2-chloropyridine 
• 504-29-0 2-aminopyridine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 77278-62-7 tert-butyl 4-(pyridin-2-yl)piperazine-1-carboxylate 
• 109-04-6 2-bromo-pyridine 
• 158399-58-7 ethyl-4-(2-pyridyl)-1-piperazine carboxylate 

Downstream Products

• 57260-42-1 5-phenyl-2-(4-pyridin-2-yl-piperazin-1-yl)-oxazol-4-one 
• 1025811-92-0 2-(3-methoxy-2-phenethyloxy-phenyl)-1-(4-pyridin-2-yl-piperazin-1-yl)-ethanone 
• 40004-68-0 2-<4-(pyridin-2-yl)piperazin-1-yl>ethanol 

Relevant articles and documents

Substituted indole compound and method and use thereof

The invention provides a new indole compound, pharmaceutically acceptable salts and medicinal preparations thereof, and a use of the new indole compound in selective inhibition of 5-hydroxytryptamine reuptake and /or excitation of a 5-HT1A receptor. The invention also relates to medicinal compositions comprising the compounds, and a method for treating the central nervous system dysfunction of mammals, especially humans by using the medicinal compositions.

Pd-Catalyzed Synthesis of Piperazine Scaffolds under Aerobic and Solvent-Free Conditions

A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.

Discovery of a novel 5-HT3 antagonist/5-HT1A agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl} quinazolin-4(3 H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome

We have prepared a series of quinazolinone derivatives linked with piperazinylquinoline for the treatment of irritable bowel syndrome (IBS). Using pharmacophore analysis, we designed and synthesized compounds which bind to both serotonin receptor subtype 1A (5-HT1A) and subtype 3 (5-HT 3). Quinazolinone derivatives with a sulfur atom in the linker showed high affinity in in vitro assays, but low in vivo activity. Focusing on the linker to improve the pharmacokinetic profile, the sulfur atom in the linker was replaced with a methylene group. Further optimization led to the discovery of compound 17m (TZB-30878) (J. Pharmacol. Exp. Ther. 2007, 322, 1315 -1323, Patent WO2005082887 (A1), 2005), a novel 5-HT1A agonist/5-HT3 antagonist in the 3-aminoquinazolinone series. In in vivo functional assays, 17m dose dependently inhibited the Bezold-Jarisch reflex and induced 5-HT 1A-mediated behaviors, and in an IBS animal model, 17m significantly inhibited stress-induced defecation. Pretreatment by WAY-100635 (5-HT 1A antagonist) significantly attenuated but did not abolish the inhibitory effects of 17m. These results suggested that 17m exerted inhibitory effects via both 5-HT1A agonistic and 5-HT3 antagonistic activities and that 17m would be useful as a therapeutic agent for IBS.